Biocon Subsidiary Receives USFDA Approval for Yesintek Prefilled Autoinjector

Biocon Ltd announced on Tuesday that its United States-based subsidiary has received supplemental approval from the US Food and Drug Administration (USFDA) for the Yesintek prefilled autoinjector.

According to a regulatory filing by the company, the supplemental approval covers the 45 mg/0.5 ml and 90 mg/ml single-dose prefilled autoinjector strengths of Yesintek. The medication was originally approved by the US health regulator on November 29, 2024.

The newly approved single-dose prefilled autoinjector format is intended to provide patients with an additional treatment option. Biocon stated that this delivery format supports tailored treatment approaches across various care settings and patient requirements.

Yesintek is indicated for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients aged six years and older. Additionally, the drug is indicated for moderately to severely active Crohn's disease and ulcerative colitis in adults. These autoimmune conditions affect tens of thousands of patients in the United States.

The company noted that this supplemental approval expands its immunology product portfolio in the United States. Biocon stated that the development reinforces its focus on broadening access to affordable medicines for patients globally.

"Regulatory approvals in major international markets like the United States are critical for scaling global pharmaceutical operations. Securing supplemental approvals for new delivery formats, such as prefilled autoinjectors, allows companies to better address diverse patient needs and expand their market reach within competitive therapeutic segments like immunology." — Dr. Shishir Gupta, Founder & CEO, StartupLanes